FDA approves Stanford Medicine-developed drug that treats rare heart disease
The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed with a rare cardiovascular disease, transthyretin amyloid cardiomyopathy, or ATTR-CM.